207 related articles for article (PubMed ID: 16919703)
1. Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen.
Sakhatskyy P; Wang S; Chou TH; Lu S
Virology; 2006 Nov; 355(2):164-74. PubMed ID: 16919703
[TBL] [Abstract][Full Text] [Related]
2. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions.
Fogg C; Lustig S; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B
J Virol; 2004 Oct; 78(19):10230-7. PubMed ID: 15367588
[TBL] [Abstract][Full Text] [Related]
3. Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.
Golden JW; Zaitseva M; Kapnick S; Fisher RW; Mikolajczyk MG; Ballantyne J; Golding H; Hooper JW
Virol J; 2011 Sep; 8():441. PubMed ID: 21933385
[TBL] [Abstract][Full Text] [Related]
4. A Nucleic Acid-Based Orthopoxvirus Vaccine Targeting the Vaccinia Virus L1, A27, B5, and A33 Proteins Protects Rabbits against Lethal Rabbitpox Virus Aerosol Challenge.
Mucker EM; Golden JW; Hammerbeck CD; Kishimori JM; Royals M; Joselyn MD; Ballantyne J; Nalca A; Hooper JW
J Virol; 2022 Feb; 96(3):e0150421. PubMed ID: 34851148
[TBL] [Abstract][Full Text] [Related]
5. Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge.
Xiao Y; Zeng Y; Alexander E; Mehta S; Joshi SB; Buchman GW; Volkin DB; Middaugh CR; Isaacs SN
Vaccine; 2013 Jan; 31(2):319-26. PubMed ID: 23153450
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens.
Sakhatskyy P; Wang S; Zhang C; Chou TH; Kishko M; Lu S
Virology; 2008 Feb; 371(1):98-107. PubMed ID: 17950773
[TBL] [Abstract][Full Text] [Related]
7. Short-term and longer-term protective immune responses generated by subunit vaccination with smallpox A33, B5, L1 or A27 proteins adjuvanted with aluminum hydroxide and CpG in mice challenged with vaccinia virus.
Xiao Y; Zeng Y; Schante C; Joshi SB; Buchman GW; Volkin DB; Middaugh CR; Isaacs SN
Vaccine; 2020 Aug; 38(38):6007-6018. PubMed ID: 32741672
[TBL] [Abstract][Full Text] [Related]
8. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge.
Pulford DJ; Gates A; Bridge SH; Robinson JH; Ulaeto D
Vaccine; 2004 Sep; 22(25-26):3358-66. PubMed ID: 15308360
[TBL] [Abstract][Full Text] [Related]
9. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates.
Hooper JW; Custer DM; Thompson E
Virology; 2003 Feb; 306(1):181-95. PubMed ID: 12620810
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge.
Thornburg NJ; Ray CA; Collier ML; Liao HX; Pickup DJ; Johnston RE
Virology; 2007 Jun; 362(2):441-52. PubMed ID: 17292434
[TBL] [Abstract][Full Text] [Related]
11. Protection of Mice from Lethal Vaccinia Virus Infection by Vaccinia Virus Protein Subunits with a CpG Adjuvant.
Reeman S; Gates AJ; Pulford DJ; Krieg A; Ulaeto DO
Viruses; 2017 Dec; 9(12):. PubMed ID: 29232844
[TBL] [Abstract][Full Text] [Related]
12. Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge.
Fogg CN; Americo JL; Earl PL; Resch W; Aldaz-Carroll L; Eisenberg RJ; Cohen GH; Moss B
J Virol; 2008 Aug; 82(16):8022-9. PubMed ID: 18524827
[TBL] [Abstract][Full Text] [Related]
13. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge.
Hooper JW; Golden JW; Ferro AM; King AD
Vaccine; 2007 Feb; 25(10):1814-23. PubMed ID: 17240007
[TBL] [Abstract][Full Text] [Related]
14. Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response.
Paran N; Lustig S; Zvi A; Erez N; Israely T; Melamed S; Politi B; Ben-Nathan D; Schneider P; Lachmi B; Israeli O; Stein D; Levin R; Olshevsky U
Virol J; 2013 Jul; 10():229. PubMed ID: 23842430
[TBL] [Abstract][Full Text] [Related]
15. Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.
Clark KM; Johnson JB; Kock ND; Mizel SB; Parks GD
Virology; 2011 Oct; 419(2):97-106. PubMed ID: 21885079
[TBL] [Abstract][Full Text] [Related]
16. Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein.
Kaever T; Meng X; Matho MH; Schlossman A; Li S; Sela-Culang I; Ofran Y; Buller M; Crump RW; Parker S; Frazier A; Crotty S; Zajonc DM; Peters B; Xiang Y
J Virol; 2014 Oct; 88(19):11339-55. PubMed ID: 25031354
[TBL] [Abstract][Full Text] [Related]
17. Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.
Braxton CL; Puckett SH; Mizel SB; Lyles DS
J Virol; 2010 Apr; 84(7):3552-61. PubMed ID: 20089648
[TBL] [Abstract][Full Text] [Related]
18. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge.
Lustig S; Fogg C; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B
J Virol; 2005 Nov; 79(21):13454-62. PubMed ID: 16227266
[TBL] [Abstract][Full Text] [Related]
19. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
[TBL] [Abstract][Full Text] [Related]
20. Co-administration of recombinant major envelope proteins (rA27L and rH3L) of buffalopox virus provides enhanced immunogenicity and protective efficacy in animal models.
Kumar A; Yogisharadhya R; Venkatesan G; Bhanuprakash V; Pandey AB; Shivachandra SB
Antiviral Res; 2017 May; 141():174-178. PubMed ID: 28259752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
